BioLight Life Sciences Ltd. (IL:BOLT)
TASE:BOLT
Want to see IL:BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
371.40
-0.16(-2.50%)
At close: 4:00 PM EST
371.40
-0.16(-2.50%)
Day’s Range― - ―
52-Week Range209.20 - 636.70
Previous CloseN/A
Volume1.67K
Average Volume (3M)11.86K
Market Cap
₪30.47M
Enterprise Value14.41M
Total Cash (Recent Filing)₪23.65M
Total Debt (Recent Filing)₪772.00K
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Supportive SolvencyConsistently minimal debt reduces refinancing and solvency risk, giving management structural financial flexibility. For a pre-commercial biotech this lowers near-term default risk, preserves options to raise R&D capital on less onerous terms, and supports multi-quarter runway planning.
Extremely Lean Operating FootprintA very small headcount limits fixed payroll and overhead, which durably reduces baseline cash burn versus larger peers. This lean structure improves operational flexibility, allowing management to direct scarce resources to core R&D priorities and extend runway between financings.
R&D-focused Pre-commercial ModelA sustained R&D orientation signals that capital is being invested in product and pipeline development rather than short-term sales. If clinical or regulatory milestones are met, this structural focus can translate into step-change revenue and durable competitive assets typical of successful biotech commercialization paths.
Bears Say
Revenue Fell To Zero In 2025A drop to zero reported revenue shows the company currently lacks commercialized products and cannot self-sustain operations from sales. Over the medium term this forces repeated external financings, increases dilution risk, and delays any pathway to stable operating margins and cash generation.
Persistent Negative Operating Cash FlowMaterial negative operating cash flow across years indicates real cash burn rather than accounting losses. This structural outflow creates ongoing dependence on capital markets or partners, compresses strategic optionality, and raises vulnerability to funding disruptions or higher-cost financing over multiple quarters.
Eroding Equity And Sustained Operating LossesMeaningful equity erosion from multi-year losses reduces the capital cushion available to absorb shocks or invest in scale-up. Structurally negative returns and shrinking equity limit strategic choices, increase default or dilution risk if funding conditions worsen, and constrain long-term growth investments.
BOLT FAQ
What was BioLight Life Sciences Ltd.’s price range in the past 12 months?
BioLight Life Sciences Ltd. lowest stock price was 209.20 and its highest was 636.70 in the past 12 months.
What is BioLight Life Sciences Ltd.’s market cap?
BioLight Life Sciences Ltd.’s market cap is ₪30.47M.
When is BioLight Life Sciences Ltd.’s upcoming earnings report date?
BioLight Life Sciences Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 82 days.
How were BioLight Life Sciences Ltd.’s earnings last quarter?
BioLight Life Sciences Ltd. released its earnings results on Apr 01, 2026. The company reported -67.2 earnings per share for the quarter, missing the consensus estimate of N/A by -67.2.
Is BioLight Life Sciences Ltd. overvalued?
According to Wall Street analysts BioLight Life Sciences Ltd.’s price is currently Overvalued.
Does BioLight Life Sciences Ltd. pay dividends?
BioLight Life Sciences Ltd. does not currently pay dividends.
What is BioLight Life Sciences Ltd.’s EPS estimate?
BioLight Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLight Life Sciences Ltd. have?
BioLight Life Sciences Ltd. has 9,079,270 shares outstanding.
What happened to BioLight Life Sciences Ltd.’s price movement after its last earnings report?
BioLight Life Sciences Ltd. reported an EPS of -67.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioLight Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IL:BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLight Life Sciences Ltd.
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.